Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute
About this trial
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
Eligibility criteria
Qualifiers
Age 18 or older
English speaking
Ability to understand and willingness to provide oral consent
DFCI patient who are in remission from a blood cancer >1 year will be preferred.
Disqualifiers
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers <18 years old)
Prisoners.
Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1
Trial design
Treatments tested in this trial
- DIVERSE Review Process
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Dana-Farber Cancer Institute
Lead sponsor
National Cancer Institute (NCI)
Collaborator
American Society of Clinical Oncology
Collaborator
Source ClinicalTrials.gov